Moreover, we identified specific gut microbiota, such as Lachnospiraceae FCS020 and Ruminococcaceae UCG009, and inflammatory cytokines, such as IL-18 and MIP-1b, as potential mediators in the causal effect of these lipid-lowering drug targets on IBD, CD, and UC. This evidence concerns the gene IL18 and inflammatory bowel disease.